Table 1. Patient data.
| At diagnosis | At end of study | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Gender | Age | Treatment | Up/c | eGFR | Albumin | Histologic type | Up/c | eGFR | Primary outcome (1–6) |
| 1 | M | 10 | CSA | 1.98 | 184.9 | 2.9 | NOS | 2.35 | 264.4 | 4 |
| 2 | F | 14 | CSA | 2.63 | 164.7 | 3.4 | NOS | 0.41 | 150.8 | 3 |
| 3 | F | 14 | CSA | 4.34 | 171.1 | 3.2 | NOS | 0.45 | 144 | 3 |
| 4 | F | 37 | CSA | 3.28 | 76.5 | 3.6 | NOS | 0.75 | 71.7 | 2 |
| 5 | M | 12 | CSA | 2.85 | 112.2 | 3.6 | Perihilar | 0.36 | 108.2 | 4 |
| 6 | M | 35 | CSA | 1.29 | 56.4 | 3.6 | NOS | 0.8 | 47.9 | 6 |
| 7 | M | 26 | CSA | 2.76 | 83.3 | 3.4 | Perihilar | 1.46 | 56.7 | 3 |
| 8 | M | 27 | MMF | 3.94 | 84 | 3.3 | Tip | 1.73 | 77.9 | 4 |
| 9 | F | 35 | MMF | 2.95 | 95.3 | 3.6 | Collapsing | 2.77 | 32.8 | 6 |
| 10 | M | 37 | MMF | 2.58 | 53.8 | 4.0 | NOS | 3.56 | 26 | 6 |
| 11 | M | 36 | MMF | 2.26 | 127.8 | 3.4 | Tip | 0.56 | 149.2 | 3 |
| 12 | F | 34 | MMF | 2.17 | 64.0 | 3.4 | Perihilar | 2.75 | 58.4 | 3 |
| 13 | M | 30 | MMF | 1.04 | 111.2 | 4.6 | Tip | 0.21 | 105.9 | 3 |
| 14 | M | 15 | MMF | 3.15 | 152.3 | 2.8 | NOS | 0.07 | 154.9 | 1 |
| 15 | F | 14 | MMF | 4.76 | 53.7 | 3.4 | Perihilar | 1.63 | 44.2 | 3 |
| 16 | M | 13 | MMF | 15.22 | 87.9 | 1.2 | Collapsing | - | - | 6 |
| 17 | F | 13 | MMF | 15.31 | 86.6 | 2.2 | Tip | 0.06 | 132.8 | 2 |
| 18 | F | 26 | MMF | 4.07 | 189.1 | 3.8 | NOS | 1.64 | 224.2 | 3 |
| 19 | F | 12 | MMF | 1.04 | 206.3 | 3.7 | NOS | 0.06 | 178.6 | 1 |
Abbreviations: cyclosporine, CSA; mycophenolate mofetil, MMF; Not otherwise specified, NOS.